This phase III trial is trying to understand how safe and effective a targeted therapy drug (DS-1062a) is compared to chemotherapy (docetaxel) in people with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations.
This trial is treating patients with non-small cell lung cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has not spread to other parts of the body.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-LUNG01)
Daiichi Sankyo Ltd.
This randomised trial has experimental and active comparator arms. Participants in the Experimental Arm will be randomised to receive 6.0mg/kg of DS-1062a (intravenously) on Day 1 of each 3-week cycle. Participants in the Active comparator arm will be randomised to receive 75 mg/m^2 docetaxel (intravenously) on Day 1 of each 3-week cycle.
Not Recruiting Hospitals Read More